Skip to main content
Signal8
Launch Terminal

SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.

Sector: Pharmaceutical Preparations

Industry: Drug Manufacturers - Specialty & Generic

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

NASDAQ:SUPNHealthcare
+0.19%$41.92
AH$41.92+0.00%vs close
Mkt Cap$2.44B
Float55.54M
O/S58.24M
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
Supernus Pharmaceuticals, Inc. logoNASDAQ:SUPNHalted T12$41.92+0.19%
Upcoming Catalysts
Phase Distribution
67 lead-sponsored trials·9 active·48 completed
Early Phase 11
Phase 110
Phase 1/24
Phase 218
Phase 320
Phase 48
Not applicable6
(6 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Recent Deals
  • Indivior Pharmaceuticals, Inc.COLLAB
    Nov 2, 2026
    Supernus CNS portfolioIndivior portfolio
Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Completed

    Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

    APOKYN, L-dopa

    Parkinson's Disease, Motor Symptoms +3

    Enrollment
    127
    Start
    Dec 2012
    Primary Completion
    Apr 2014
    Completion
    Apr 2014
    NCT01770145
  • Phase 4
    Terminated

    Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®

    APOKYN

    Parkinson's Disease, Motor Symptoms

    Enrollment
    13
    Start
    Jan 2016
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT02549573
  • Phase 4
    Terminated

    Therapy for Migraine Prevention in Children 6-11 Years of Age

    SPN-538, Placebo

    Migraine Disorders, Headache Disorders

    Enrollment
    26
    Start
    Jul 2020
    Primary Completion
    Mar 2023
    Completion
    Mar 2023
    NCT04050293
  • Phase 4
    Recruiting

    Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

    100mg SPN-812, Placebo

    Attention-Deficit/Hyperactivity Disorder

    Enrollment
    286
    Start
    Mar 2024
    Primary Completion
    Jan 2028est.
    Completion
    Jan 2028est.
    NCT04781140
  • Phase 4
    Completed

    Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD

    SPN-812

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    Enrollment
    96
    Start
    Jul 2021
    Primary Completion
    May 2023
    Completion
    Jul 2023
    NCT04786990
  • Phase 4
    Completed

    A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting

    ZULRESSO®

    Postpartum Depression

    Enrollment
    52
    Start
    Oct 2021
    Primary Completion
    Jul 2022
    Completion
    Jul 2022
    NCT05059600
  • Phase 4
    Completed

    Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms

    SPN-812

    Attention-Deficit/Hyperactivity Disorder

    Enrollment
    161
    Start
    Mar 2024
    Primary Completion
    Dec 2024
    Completion
    Dec 2024
    NCT06185985
  • Phase 4
    Completed

    Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women

    SPN-812 (600mg, QD)

    Healthy Lactating Women

    Enrollment
    15
    Start
    May 2023
    Primary Completion
    Sep 2023
    Completion
    Sep 2023
    NCT06259331
  • Phase 3
    Completed

    Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures

    Placebo, 2400mg SPN-804

    Epilepsies, Partial

    Enrollment
    366
    Start
    Nov 2008
    Primary Completion
    Apr 2010
    Completion
    Nov 2010
    NCT00772603
  • Phase 3
    Completed

    Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

    Oxcarbazepine XR

    Partial Epilepsy

    Enrollment
    214
    Start
    Jun 2009
    Primary Completion
    Nov 2011
    Completion
    Nov 2011
    NCT00908349
  • Phase 3
    Active, not recruiting

    Infusion of Apomorphine: Long-term Safety Study

    apomorphine infusion

    Idiopathic Parkinson's Disease

    Enrollment
    99
    Start
    Feb 2015
    Primary Completion
    Dec 2018
    Completion
    Dec 2025est.
    NCT02339064
  • Phase 3
    Completed

    A Study With SAGE-547 for Super-Refractory Status Epilepticus

    SAGE-547, Placebo

    Super-Refractory Status Epilepticus

    Enrollment
    132
    Start
    Jun 2015
    Primary Completion
    Jul 2017
    Completion
    Aug 2017
    NCT02477618
  • Phase 3
    Completed

    Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)

    SPN-810 (18 mg), SPN-810 (36 mg)

    Attention Deficit Hyperactivity Disorder (ADHD)

    Enrollment
    333
    Start
    Jan 2016
    Primary Completion
    Sep 2019
    Completion
    Oct 2019
    NCT02618408
  • Phase 3
    Completed

    Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

    SPN-810 (18 mg), SPN-810 (36 mg)

    Attention Deficit Hyperactivity Disorder (ADHD)

    Enrollment
    297
    Start
    Feb 2016
    Primary Completion
    Nov 2019
    Completion
    Feb 2020
    NCT02618434
  • Phase 3
    Terminated

    Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)

    SPN-810

    Attention Deficit Hyperactivity Disorder (ADHD)

    Enrollment
    491
    Start
    Apr 2016
    Primary Completion
    May 2021
    Completion
    May 2021
    NCT02691182
  • Phase 3
    Active, not recruiting

    Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

    SPN-812

    Attention-Deficit/Hyperactivity Disorder

    Enrollment
    1,400
    Start
    Feb 2016
    Primary Completion
    Sep 2026est.
    Completion
    Sep 2026est.
    NCT02736656
  • Phase 3
    Completed

    A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)

    Placebo, SAGE-547 60 μg/kg/h

    Postpartum Depression

    Enrollment
    138
    Start
    Aug 2016
    Primary Completion
    Sep 2017
    Completion
    Oct 2017
    NCT02942004
  • Phase 3
    Completed

    A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

    Placebo, SAGE-547 90 μg/kg/h

    Postpartum Depression

    Enrollment
    108
    Start
    Jul 2016
    Primary Completion
    Sep 2017
    Completion
    Oct 2017
    NCT02942017
  • Phase 3
    Completed

    Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

    Placebo, 200mg SPN-812

    ADHD

    Enrollment
    310
    Start
    Nov 2017
    Primary Completion
    Oct 2018
    Completion
    Oct 2018
    NCT03247517
  • Phase 3
    Completed

    Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD

    Placebo, 100mg SPN-812

    ADHD

    Enrollment
    477
    Start
    Oct 2017
    Primary Completion
    Sep 2018
    Completion
    Sep 2018
    NCT03247530
  • Phase 3
    Completed

    Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD

    Placebo, 200mg SPN-812

    ADHD

    Enrollment
    313
    Start
    Oct 2017
    Primary Completion
    Oct 2018
    Completion
    Oct 2018
    NCT03247543
  • Phase 3
    Completed

    Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD

    Placebo, 400mg SPN-812

    ADHD

    Enrollment
    297
    Start
    Nov 2017
    Primary Completion
    Feb 2019
    Completion
    Feb 2019
    NCT03247556
  • Phase 3
    Terminated

    Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment

    SPN-810, Placebo

    Attention Deficit Hyperactivity Disorder

    Enrollment
    41
    Start
    Jul 2018
    Primary Completion
    Jan 2020
    Completion
    Jan 2020
    NCT03597503
  • Phase 3
    Completed

    A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)

    Brexanolone

    Post Partum Depression

    Enrollment
    28
    Start
    Sep 2018
    Primary Completion
    Jan 2021
    Completion
    Jan 2021
    NCT03665038
  • Phase 3
    Completed

    Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

    Placebo, SPN-812

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    Enrollment
    374
    Start
    Nov 2019
    Primary Completion
    Oct 2020
    Completion
    Oct 2020
    NCT04016779

1-25 of 67

Search ClinicalTrials.gov for “Supernus Pharmaceuticals”